{
    "nct_id": "NCT03800134",
    "official_title": "A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)",
    "inclusion_criteria": "* Age â‰¥18 years\n* Newly diagnosed and previously untreated patients with histologically or cytologically documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB) disease\n* World Health Organization (WHO)/ECOG PS of 0 or 1 at enrollment\n* At least 1 lesion, not previously irradiated, that qualifies as a RECIST 1.1 Target Lesion (TL) at baseline\n* No prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-PD-L2 antibodies, excluding therapeutic anticancer vaccines\n* Adequate organ and marrow function\n* Confirmation of a patient's tumour PD-L1 status\n* Provision of sufficient tumour biopsy sample for evaluation and confirmation of EGFR and ALK status\n* Planned surgery must comprise lobectomy, sleeve resection, or bilobectomy\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "* History of allogeneic organ transplantation\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome)\n* History of another primary malignancy\n* History of active primary immunodeficiency\n* Active infection including tuberculosis hepatitis B and C, or human immunodeficiency virus\n* Deemed unresectable NSCLC by multidisciplinary evaluation\n* Patients who have pre-operative radiotherapy treatment as part of their care plan\n* Patients who have brain metastases or spinal cord compression\n* Stage IIIB N3 and Stages IIIC, IVA, and IVB NSCLC\n* Known allergy or hypersensitivity to any of the study drugs or excipients\n* Existence of more than one primary tumour such as mixed small cell and NSCLC histology\n* Patients whose planned surgery at enrollment includes any of the following procedures: pneumonectomy, segmentectomies, or wedge resections\n* Patients with a documented test result confirming the presence of EGFRm or ALK translocation",
    "miscellaneous_criteria": ""
}